AI in Respiratory Diseases Market Report 2026

The artificial intelligence (AI) in respiratory diseases market size has grown steadily in recent years. It will grow from $7.98 billion in 2025 to $8.38 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising incidence of respiratory diseases, increased use of ct and mri imaging, growing digitalization of healthcare records, early adoption of ai-assisted diagnostics, expansion of hospital diagnostic capabilities.

The artificial intelligence (AI) in respiratory diseases market size is expected to see strong growth in the next few years. It will grow to $10.19 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory care, rising integration of ai with clinical decision support systems, expansion of remote monitoring for chronic respiratory patients, growing focus on preventive pulmonology, advancements in medical imaging ai. Major trends in the forecast period include increasing use of AI-based imaging analysis, rising adoption of predictive disease progression models, growing integration of ai in pulmonary diagnostics, expansion of remote respiratory monitoring solutions, enhanced focus on early disease detection.

The respiratory disease market is expected to grow going forward. Environmental pollution involves the introduction of any substance or form of energy into the environment at a rate faster than it can be safely absorbed or neutralized. AI in respiratory diseases can significantly mitigate the effects of environmental pollution on respiratory health by providing real-time monitoring, personalized risk assessments, informed decision-making, and innovative solutions for both individuals and communities. For example, in November 2024, according to the Global Carbon Budget, a Japan-based annual scientific assessment, fossil carbon dioxide emissions reached 37.4 billion tonnes, marking an increase of 0.8% compared to the previous year. Consequently, the rising environmental pollution is driving the growth of artificial intelligence (AI) in the respiratory disease market.

Major companies operating in artificial intelligence (AI) within the respiratory diseases market are creating innovative solutions such as N-Tidal devices to monitor patients' tidal breathing. The N-Tidal device tracks the volume of air exchanged during normal breathing and provides important insights into lung function. For example, in August 2023, TidalSense, a UK-based respiratory technology company, introduced N-Tidal, a regulated AI technology for the diagnosis and management of chronic obstructive pulmonary disease (COPD). This technology integrates N-Tidal's CO2 sensor data with an artificial intelligence platform to assess changes in lung function, aiming to enhance the diagnosis and management of this respiratory condition. Clinical studies have shown the technology’s high accuracy, and it is anticipated to transform the diagnostic process for respiratory diseases. The launch represents a significant advancement in the application of AI for respiratory disease evaluation, offering a more comfortable and efficient alternative to conventional diagnostic tests.

In July 2023, ResMed Inc., a US-based medical equipment company offering cloud-connectable medical devices, acquired Somnoware for an undisclosed amount. This acquisition enhances ResMed's sleep and respiratory care portfolio and complements its existing digital respiratory healthcare solutions. The acquisition is expected to improve the management of patient data, ordering of treatment equipment, appointment scheduling, and compliance tracking, ultimately benefiting patient experience and health outcomes. Somnoware is a US-based, cloud platform focused on advanced respiratory care management and hospital-at-home care.

Major companies operating in the artificial intelligence (AI) in respiratory diseases market are Siemens Healthineers, Philips Healthcare, GE Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative L.P., Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Swaasa AI, VIDA Diagnostics Inc., Enlitic, Thirona B.V., ArtiQ, Icometrix, Aidence, Arterys, PneumoWave Ltd.

North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in respiratory diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in respiratory diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the artificial intelligence in respiratory diseases market by increasing costs of imported imaging hardware, diagnostic sensors, high-performance computing systems, and data processing equipment. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported medical imaging technology, while Asia-Pacific faces higher capital costs for system deployment. These tariffs are slowing equipment upgrades and adoption rates. However, they are also encouraging localized manufacturing of imaging devices, domestic software innovation, and greater focus on cloud-based AI diagnostic solutions.

The artificial intelligence (AI) in respiratory diseases market research report is one of a series of new reports that provides artificial intelligence (AI) in respiratory diseases market statistics, including artificial intelligence (AI) in respiratory diseases industry global market size, regional shares, competitors with a artificial intelligence (AI) in respiratory diseases market share, detailed artificial intelligence (AI) in respiratory diseases market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in respiratory diseases industry. This artificial intelligence (AI) in respiratory diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) in respiratory diseases involves the application of AI and machine learning methods to assist clinicians in diagnosing, managing, and treating a variety of respiratory conditions. It offers numerous potential uses in pulmonary medicine, such as image analysis, predictive modeling, and disease management.

The primary imaging types of artificial intelligence (AI) in respiratory diseases include magnetic resonance imaging (MRI), computed tomography (CT) scans, and electronic patient-reported outcomes (ePRO). AI in chronic obstructive pulmonary disease involves the use of artificial intelligence (AI) technologies for the diagnosis, management, and treatment of COPD. It is utilized for managing various conditions such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infections by multiple end-users, including hospitals, diagnostic centers, ambulatory surgical centers, and others.

The artificial Intelligence (AI) in respiratory diseases market includes revenues earned by entities by providing services such as AI-assisted imaging analysis, digital pathology platforms, and AI-powered rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in respiratory diseases market also includes sales IoT devices, wearables, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.